Bone Therapeutics
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
Bone Therapeutics (0R55) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.052x
Based on the latest financial reports, Bone Therapeutics (0R55) has a cash flow conversion efficiency ratio of 0.052x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.39 Million) by net assets (€-26.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bone Therapeutics - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Bone Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bone Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Song Da 505 JSC
VN:S55
|
N/A |
|
CORONATION FD MANAG
BE:N8C
|
N/A |
|
Keystone Law Group PLC
LSE:KEYS
|
0.375x |
|
DAR ES SALAAM STOCK EXCHANGE PLC
DSE:DSE
|
N/A |
|
LREN3F
SA:LREN3F
|
N/A |
|
Altitude International Holdings Inc
PINK:ALTD
|
-0.125x |
|
UACJ Corp
OTCMKTS:UACJF
|
N/A |
|
Union Financial Corporation
PINK:UFCP
|
N/A |
Annual Cash Flow Conversion Efficiency for Bone Therapeutics (2012–2024)
The table below shows the annual cash flow conversion efficiency of Bone Therapeutics from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-26.81 Million | €-2.23 Million | 0.083x | -45.50% |
| 2023-12-31 | €-22.70 Million | €-3.47 Million | 0.153x | +125.00% |
| 2022-12-31 | €3.12 Million | €-1.91 Million | -0.611x | -132.35% |
| 2021-12-31 | €-6.76 Million | €-12.78 Million | 1.890x | +139.07% |
| 2020-12-31 | €3.33 Million | €-16.08 Million | -4.837x | +4.75% |
| 2019-12-31 | €2.05 Million | €-10.40 Million | -5.078x | -76.78% |
| 2018-12-31 | €4.49 Million | €-12.90 Million | -2.873x | +37.87% |
| 2017-12-31 | €2.38 Million | €-11.02 Million | -4.624x | -521.01% |
| 2016-12-31 | €15.27 Million | €-11.37 Million | -0.745x | -78.12% |
| 2015-12-31 | €28.15 Million | €-11.77 Million | -0.418x | -212.50% |
| 2014-12-31 | €-9.48 Million | €-3.52 Million | 0.372x | +100.71% |
| 2013-12-31 | €63.00K | €-3.27 Million | -51.968x | -3284.99% |
| 2012-12-31 | €2.64 Million | €-4.05 Million | -1.535x | -- |